Is your patient with Rheumatoid Arthritis starting treatment with any of the following therapies?

**New participants to the BSRBR-RA can be registered within 6 months of the drug start date.**

- Database Access: https://bsrbr.org/database/
- Registration Forms: https://bsrbr.org/hospitals/data-collection/

If you have any questions please contact the team: biologics.register@manchester.ac.uk

---

**Biosimilars**
- Adalimumab biologics
- Amgevita
- Hulio
- Hyrimoz
- Idacio
- Imraldi
- Yuflyma
- Rituximab biosimilars
- Rixathon
- Ruxience

**Other targeted therapies**
- Etanercept biosimilars
- Benepali
- Erelzi
- Infliximab biosimilars
- Flixbio
- Inflectra
- Remsima IV
- Remsima SC
- Baricitinib
- Olumiant
- Certolizumab
- Cimzia
- Tocilizumab
- RoActemra
- Sarilumab
- Kevzara
- Upadacitinib
- Rinvoq

**ANTI-TNF originators**
- Adalimumab originator
- Humira
- Etanercept originator
- Enbrel
- Infliximab originator
- Remicade

---

**Is the patient already on the register?**

**YES**

You can **re-register** this person with the BSRBR-RA study.
- If the person is happy to be re-registered*, ask them to read the Participant Information Sheet and transparency information sheet, then re-consent the patient.
- Ask them to complete a HAQ and EQ5D.
- Use the “Switch cohort” function to re-register the patient; the team will advise you on the next steps.

*If they decline re-registration, please note this at the next follow up.

**NO**

**New participants to the BSRBR-RA can be registered within 6 months of the drug start date.**

Please give the person the Participant Information Sheet and transparency information sheet.

If they want to take part, take consent and register them by entering the below data on the BSRBR-RA online database:
- Clinical baseline information
- HAQ
- EQ-5D
- Upload a copy of the signed consent form

---

If you will not be seeing the participant in clinic within the recruitment window (6 months for participants who are new to the study, 24 months for those being re-registered), there is an ‘outreach consent’ option for obtaining consent remotely. Please see the information here: https://bsrbr.org/hospitals/eligibility/consent-process/

---

**Is the patient biologic, biosimilar & targeted therapy naive?**

**YES**

**NO**

**Sorry. This patient is not eligible for registration.**